Cargando…

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States

BACKGROUND: Ustekinumab has been recently approved for the treatment of moderately to severely active ulcerative colitis (UC). The registry trials for ustekinumab in UC demonstrated efficacy and safety, but data on real-world outcomes are limited. We describe the effectiveness and safety of ustekinu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Simon J, Krugliak Cleveland, Noa, Akiyama, Shintaro, Zullow, Samantha, Yi, Yangtian, Shaffer, Seth R, Malter, Lisa B, Axelrad, Jordan E, Chang, Shannon, Hudesman, David P, Rubin, David T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802405/ https://www.ncbi.nlm.nih.gov/pubmed/36777067 http://dx.doi.org/10.1093/crocol/otab002

Ejemplares similares

Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021)

Histologic Inflammation can Predict Future Clinical Relapse in Ulcerative Colitis Patients in Endoscopic Remission
por: George, Lauren A, et al.
Publicado: (2023)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
por: Wang, Wenfei, et al.
Publicado: (2019)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

A Summary of the BRIDGe Summit on Damage-Related Progression of Ulcerative Colitis: Establishing Research Priorities
por: Cleveland, Noa Krugliak, et al.
Publicado: (2022)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis
por: Abraham, Bincy P, et al.
Publicado: (2022)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Diffuse Panbronchiolitis in a Patient With Ulcerative Colitis Treated With Ustekinumab
por: Marmor, Meghan, et al.
Publicado: (2023)

A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis
por: Zafer, Maryam, et al.
Publicado: (2021)

Factors Associated With Fecal Calprotectin Sample Collection Compliance: An IBD Center Quality Improvement Project
por: Fenton, David, et al.
Publicado: (2022)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Ethnicity Influences Risk of Inflammatory Bowel Disease (IBD)-Associated Colon Cancer: A Cross-sectional Analysis of Dysplasia Prevalence and Risk Factors in Hispanics and Non-Hispanic Whites With IBD
por: Damas, Oriana M, et al.
Publicado: (2021)

Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis
por: Kerur, Basavaraj, et al.
Publicado: (2017)

Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis
por: Núñez F, Paulina, et al.
Publicado: (2021)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis
por: Klepp, Pasquale, et al.
Publicado: (2018)

Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
por: Hu, Kelly A., et al.
Publicado: (2022)

Ustekinumab is effective against ulcerative colitis with intestinal stenosis: A case report
por: Liu, Ailing, et al.
Publicado: (2022)

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis
por: Zhao, Hong-Ying, et al.
Publicado: (2017)

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
por: Bennett, Audrey, et al.
Publicado: (2020)

Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
por: Lee, Scott David, et al.
Publicado: (2022)

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2016)

Clinical course of ulcerative colitis patients who develop acute pancreatitis
por: Kim, Jong Wook, et al.
Publicado: (2017)

Outcomes of a drug shortage requiring switching in patients with ulcerative colitis
por: van Langenberg, Daniel R, et al.
Publicado: (2020)

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy
por: Pavlidis, Polychronis, et al.
Publicado: (2022)

Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD
por: Click, Benjamin, et al.
Publicado: (2021)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis
por: He, Xu-Xia, et al.
Publicado: (2021)

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in Japan
por: Itabashi, Michio, et al.
Publicado: (2021)

Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
por: Sharma, Shreyak, et al.
Publicado: (2023)

Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
por: Ito, Takahiro, et al.
Publicado: (2020)

Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers
por: Spencer, Elizabeth A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ba6fqv2pvmp01r0hdpud6os36c